- Home
- REVB vs RSLS Comparison
REVB vs RSLS Comparison
Compare REVB & RSLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- RSLS
- Stock Information
- Founded
- REVB 2020
- RSLS 2002
- Country
- REVB United States
- RSLS United States
- Employees
- REVB N/A
- RSLS N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- RSLS Medical/Dental Instruments
- Sector
- REVB Health Care
- RSLS Health Care
- Exchange
- REVB Nasdaq
- RSLS Nasdaq
- Market Cap
- REVB 3.1M
- RSLS 3.0M
- IPO Year
- REVB N/A
- RSLS 2007
- Fundamental
- Price
- REVB $0.80
- RSLS $5.24
- Analyst Decision
- REVB
- RSLS Hold
- Analyst Count
- REVB 0
- RSLS 1
- Target Price
- REVB N/A
- RSLS N/A
- AVG Volume (30 Days)
- REVB 1.3M
- RSLS 180.6K
- Earning Date
- REVB 11-08-2024
- RSLS 11-14-2024
- Dividend Yield
- REVB N/A
- RSLS N/A
- EPS Growth
- REVB N/A
- RSLS N/A
- EPS
- REVB N/A
- RSLS N/A
- Revenue
- REVB N/A
- RSLS $8,183,000.00
- Revenue This Year
- REVB N/A
- RSLS $17.47
- Revenue Next Year
- REVB N/A
- RSLS $20.00
- P/E Ratio
- REVB N/A
- RSLS N/A
- Revenue Growth
- REVB N/A
- RSLS N/A
- 52 Week Low
- REVB $0.70
- RSLS $4.60
- 52 Week High
- REVB $25.26
- RSLS $34.22
- Technical
- Relative Strength Index (RSI)
- REVB 44.03
- RSLS 42.38
- Support Level
- REVB $0.80
- RSLS $4.88
- Resistance Level
- REVB $1.05
- RSLS $5.89
- Average True Range (ATR)
- REVB 0.07
- RSLS 0.68
- MACD
- REVB -0.00
- RSLS 0.00
- Stochastic Oscillator
- REVB 9.69
- RSLS 17.80
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.